A retrospective multicentre cohort study demonstrated that the use of sodium-glucose cotransporter type 2 inhibitors (SGLT2) is associated with a reduced risk of major cardiovascular event (MCE) in people with type 2 diabetes compared to use of a dipeptidyl peptidase-4 inhibitor (DPP-4).